Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | -0.70% | -11.32% | -24.19% |
04-22 | Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder | MT |
04-12 | Top Premarket Decliners | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 24.87 | 24.47 | 56.56 | 5.774 | 2.265 | 5.758 | - | - |
Enterprise Value (EV) 1 | 24.87 | 24.47 | 56.56 | 5.774 | 2.265 | 5.758 | 5.758 | 5.758 |
P/E ratio | -2.77 x | -1.95 x | -2.6 x | -0.42 x | -0.52 x | -0.48 x | -0.88 x | -1.23 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 413 | 576 | 838 | 1,074 | 1,218 | 4,055 | - | - |
Reference price 2 | 60.25 | 42.50 | 67.50 | 5.375 | 1.860 | 1.410 | 1.410 | 1.410 |
Announcement Date | 3/20/20 | 3/22/21 | 3/28/22 | 3/30/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -8.245 | -10.93 | -19.29 | -13.32 | -6.888 | -6.549 | -9.54 | -17.86 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -8.591 | -10.89 | -19.52 | -12.73 | -7.002 | -11.31 | -9.54 | -17.86 |
Net income 1 | -8.591 | -10.89 | -19.42 | -12.73 | -5.123 | -11.31 | -9.54 | -17.86 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -21.75 | -21.75 | -26.00 | -12.75 | -3.600 | -2.950 | -1.595 | -1.150 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/20/20 | 3/22/21 | 3/28/22 | 3/30/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -5.981 | -3.059 | -3.83 | -3.188 | -3.24 | -2.921 | -1.477 | -1.358 | -1.784 | -1.845 | -1.625 | -1.625 | -1.625 | -1.55 | -1.55 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -5.925 | -2.908 | -3.848 | -3.109 | -2.867 | -2.906 | -1.51 | -1.348 | -1.904 | -6.477 | -1.61 | -1.61 | -1.61 | -1.55 | -1.55 |
Net income 1 | -5.831 | -2.908 | -3.848 | -3.109 | -2.867 | -2.906 | 1.088 | -1.4 | -1.92 | -6.477 | -1.61 | -1.61 | -1.61 | -1.55 | -1.55 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -7.000 | -3.250 | -4.000 | -3.000 | -2.750 | -2.750 | 0.9600 | -1.180 | -0.7400 | -2.190 | -0.3900 | -0.3900 | -0.3900 | -0.3400 | -0.3100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/28/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/30/23 | 5/12/23 | 8/21/23 | 11/14/23 | 4/1/24 | 5/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/20/20 | 3/22/21 | 3/28/22 | 3/30/23 | 4/1/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.19% | 5.76M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- ADIL Stock
- Financials Adial Pharmaceuticals, Inc.